University of Chicago, Chicago, IL, USA.
Mediterr J Hematol Infect Dis. 2011;3(1):e2011019. doi: 10.4084/MJHID.2011.019. Epub 2011 May 16.
Therapy-related myeloid neoplasm (t-MN) is a distinctive clinical syndrome occurring after exposure to chemotherapy or radiotherapy. t-MN arises in most cases from a multipotential hematopoietic stem cell or, less commonly, in a lineage committed progenitor cell. The prognosis for patients with t-MN is poor, as current forms of therapy are largely ineffective. Cytogenetic analysis, molecular analysis and gene expression profiling analysis of t-MN has revealed that there are distinct subtypes of the disease; however, our understanding of the genetic basis of t-MN is incomplete. Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.
治疗相关髓系肿瘤（t-MN）是一种独特的临床综合征，发生于接触化疗或放疗后。t-MN 主要源自多能造血干细胞，或较少见地源自定向祖细胞。t-MN 患者预后较差，因为目前的治疗形式大多无效。t-MN 的细胞遗传学分析、分子分析和基因表达谱分析显示，该病存在明显的亚型；然而，我们对 t-MN 的遗传基础的理解并不完整。阐明在 t-MNs 中受到干扰的遗传途径和分子网络，可能有助于确定可用于开发急需的靶向治疗的治疗靶点。
